Age, Biography and Wiki

Robert Califf was born on 1951 in Anderson, South Carolina, U.S., is an American cardiologist (born 1951). Discover Robert Califf's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 73 years old?

Popular As N/A
Occupation N/A
Age 73 years old
Zodiac Sign N/A
Born
Birthday
Birthplace Anderson, South Carolina, U.S.
Nationality United States

We recommend you to check the complete list of Famous People born on . He is a member of famous with the age 73 years old group.

Robert Califf Height, Weight & Measurements

At 73 years old, Robert Califf height not available right now. We will update Robert Califf's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Robert Califf Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Robert Califf worth at the age of 73 years old? Robert Califf’s income source is mostly from being a successful . He is from United States. We have estimated Robert Califf's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Robert Califf Social Network

Instagram
Linkedin
Twitter Robert Califf Twitter
Facebook
Wikipedia Robert Califf Wikipedia
Imdb

Timeline

1951

Robert McKinnon Califf (born 1951) is an American cardiologist who currently serves as the 25th Commissioner of the Food and Drug Administration.

1969

He attended high school in Columbia, South Carolina where he was a member of the 1969 AAAA South Carolina Championship basketball team.

1973

He attended Duke University, graduating in 1973 summa cum laude and is a member of Phi Beta Kappa.

1978

In 1978, he graduated from the Duke University School of Medicine in Durham, North Carolina, and was inducted into the Alpha Omega Alpha medical honor society.

1980

He left North Carolina for an internal medicine residency at the University of California, San Francisco and returned in 1980 to Duke to complete a fellowship in cardiology.

1984

He is board-certified in internal medicine (1984) and cardiology (1986), and a Master of the American College of Cardiology (2006).

Califf was granted tenure as professor of cardiology at Duke University School of Medicine.

He was the founding director of the Duke Clinical Research Institute, which is considered "the world’s largest academic research organization" with 1000 employees and an annual budget of $320 million, 50-60% of which is funded from the pharmaceutical industry.

Califf led strategy and policy for Alphabet’s health subsidiaries.

He was the full-time head of strategy and policy for its Verily Life Sciences and Google Health divisions.

Califf has led many clinical cardiology research studies, health outcomes research, health care quality, and translational research, which seeks to ensure that advances in science translate into medical care.

He was a lead investigator in clinical trials testing the efficacy of the cholesterol-lowering drug combination ezetimibe/simvastatin.

2009

He was a paid consultant for Merck Sharp & Dohme, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, and Eli Lilly per ProPublica from 2009 to 2013.

2012

The largest consulting payment was $87,500 by Johnson & Johnson in 2012, and "most of funds for travel or consulting under $5,000", which has been called "minimal for a physician of his stature".

2013

From 2013 to 2014 he was paid a total of $52,796; the greatest amount being $6,450 from Merck Sharp & Dohme, followed by Amgen, F. Hoffmann-La Roche AG, Janssen Pharmaceutica, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb and AstraZeneca.

2015

Prior to becoming commissioner he had served as the Deputy Commissioner of the United States Food and Drug Administration's Office of Medical Products and Tobacco since January 2015.

As of 2015, he was vice-chancellor of clinical and translational research and the Duke Translational Medicine Institute (DTMI) director.

Califf is recognized by the Institute for Scientific Information as one of the top 10 most cited medical authors, with more than 1,200 peer-reviewed publications.

Califf worked very closely with pharmaceutical companies at the Duke clinical trials center "convincing them to do large, expensive, and, for Duke, profitable clinical trials."

He was a director of Portola Pharmaceuticals, Inc. from July 2012 to January 26, 2015, an advisor for Proventys, Inc., chairman of the medical advisory board of Regado Biosciences, Inc. and has been a member of that board since June 2, 2009, and a member of the clinical advisory board of Corgentech Inc. Forbes wrote that his close ties to the drug industry were why he was not nominated for the FDA Commissioner position in 2009.

Califf's ties to the pharmaceutical industry were criticized by the magazine The American Prospect, and Democratic Senators Bernie Sanders and Joe Manchin, who announced their intention to vote against his 2021 renomination.

In January 2015, Califf was appointed Deputy Commissioner of the United States Food and Drug Administration's Office of Medical Products and Tobacco, "second in scope only to being commissioner".

In February 2015, Califf was cited as a possible successor to Margaret Hamburg, the outgoing Commissioner of the Food and Drug Administration.

and in September 2015, President Barack Obama nominated him to be the next FDA commissioner.

2016

In February 2016, the US Senate confirmed Califf as commissioner of the Food and Drug Administration by a vote of 89-4.

2017

He was first nominated to be commissioner in September 2015 by President Barack Obama and he was confirmed by the U.S. Senate in February 2016, serving until January 20, 2017.

President Joe Biden renominated Califf to head the Food and Drug Administration on November 12, 2021.

He was confirmed by the Senate on February 15, 2022.

Califf stepped down from the post of FDA commissioner on January 20, 2017.

On November 12, 2021, President Biden announced he was nominating Califf to return as head of the FDA.

During his hearing before the Senate HELP committee on December 14, 2021, he was questioned relating to the pandemic, opioid crisis, and issues relating to abortion.

Some Democrats opposed his nomination due to his corporate ties and the opioid crisis.

Several Republican senators opposed his nomination because of issues relating to abortion.

On January 13, 2022, he was advanced out of committee by a 13-8 vote.

On February 15, 2022, the Senate confirmed his nomination by a 50-46 vote.

Califf assumed office on February 17, 2022.

He is a member of the Institute of Medicine (IOM).

He was on the committees that recommended, for example, Medicare coverage of clinical trials and to remove ephedra from the market, and the committee on identifying and preventing medication errors.

2019

In 2019, he became head of medical strategy at Google parent company Alphabet Inc.

Califf was born in Anderson, South Carolina.